Novel Application of Lutetium‐177‐Prostate Specific Membrane Antigen (LuPSMA) Radioligand Therapy for Metastatic Synovial Sarcoma

Authors:

Abstract
Intracranial synovial sarcoma is exceedingly rare, with only 24 cases reported in the literature. Given prostate specific membrane antigen (PSMA) expression is found in the neovascular endothelium of solid tumours, including sarcomas, Lutetium‐177‐PSMA (LuPSMA) presents a potential therapeutic option. The case presented here describes the first application of LuPSMA in a patient with synovial sarcoma. Our patient, a 27‐year‐old female underwent seven LuPSMA treatment cycles over the last 8 months of her life. Disease stability and prolongation in time to progression was observed across the treatment course with subjective tumour regression also seen after two cycles. Overall, our initial experience with this novel approach demonstrates proof‐of‐principle of LuPSMA treatment beyond prostate cancer, for patients with other PSMA‐expressing cancer diseases.